̽»¨Ö±²¥new ‘MN-predict’ platform will allow doctors and scientists to identify those at risk and to design new treatments to prevent them from developing these potentially lethal cancers.
Scientists have made a promising step towards developing a new drug for treating acute myeloid leukaemia, a rare blood disorder. In a study published today in Nature, Cambridge researchers report a new approach to cancer treatment that targets enzymes which play a key role in translating DNA into proteins and which could lead to a new class of cancer drugs.
Scientists at the Cambridge Institute for Medical Research at the ̽»¨Ö±²¥ of Cambridge and the Medical Research Council Laboratory of Molecular Biology have taken advantage of revolutionary developments in microscopic imaging to reveal the origins of leukaemia.
̽»¨Ö±²¥order in which genetic mutations are acquired determines how an individual cancer behaves, according to research from the ̽»¨Ö±²¥ of Cambridge, published today in the New England Journal of Medicine.
̽»¨Ö±²¥first comprehensive computer model to simulate the development of blood cells could help in the development of new treatments for leukaemia and lymphoma, say researchers at the ̽»¨Ö±²¥ of Cambridge and Microsoft Research.
New drug could treat mixed-lineage leukaemia (MLL).
Cambridge scientists are asking what role stem cells play in how cancer develops, spreads and relapses.
Cancer cells can now be viewed as never before, thanks to cutting-edge imaging tools being developed in Cambridge.
A new generation of cancer therapeutics is on the horizon thanks to fresh light being shed on how genes are switched on and off.
̽»¨Ö±²¥path from innovation to impact can be long and complex. Here we describe the 30-year journey behind the development of a drug now being used to treat multiple sclerosis.
© 2025 ̽»¨Ö±²¥ of Cambridge